Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ: AKRO )

44.12 -0.73 (-1.64%)
Streaming Delayed Price Updated: 3:57 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
3 Mid-Caps Worth Watching Closely in March
Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation. 
Via MarketBeat
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Via The Motley Fool
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
These stocks are moving in today's session
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Dow Edges Higher; AT&T Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Fall Sharply Alongside Tech; VIX Soars
Stocks are lower today amid a global tech selloff. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Traders are paying attention to the gapping stocks in Monday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday
Via Benzinga
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant
The analyst highlighted that major pharmaceutical companies are already pursuing GLP-1-based therapies for MASH, but he believes efruxifermin could complement these treatments. 
Via Stocktwits
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December
Via Benzinga
Topics Economy
Exposures Interest Rates
These stocks that are showing activity before the opening bell on Monday.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study
The companies are both working on treatments for a liver disease known as MASH. 
Via Investor's Business Daily
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver fibrosis and safety. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of... 
Via Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment. 
Via Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.